| P2093 | author name string | Lennart Estborn | |
| | Svante Joelson | |
| P2860 | cites work | BTS Guidelines for the Management of Community Acquired Pneumonia in Adults | Q24675547 |
| | Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies | Q28221704 |
| | Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety | Q31987899 |
| | Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months | Q32026591 |
| | One-week Esomeprazole Treatment: an Effective Confirmatory Test in Patients with Suspected Gastroesophageal Reflux Disease | Q33965936 |
| | Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children | Q34519895 |
| | Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs | Q34552195 |
| | The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole | Q39377527 |
| | Does gastric acid suppression increase the risk of community-acquired pneumonia? | Q40948040 |
| | A potential bias in safety evaluation during open-label extensions of randomized clinical trials. | Q42626735 |
| | Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. | Q42693997 |
| | Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial | Q43560922 |
| | The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety | Q43650344 |
| | Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial | Q43694247 |
| | Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis | Q43939369 |
| | Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months | Q44097759 |
| | Association between pulmonary and digestive infections in patients receiving gastric acid-lowering medications for a long duration | Q44233102 |
| | Gastric acid‐suppressive therapy and community‐acquired respiratory infections | Q44611999 |
| | Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis | Q44654789 |
| | Acid suppression and pneumonia: a clinical indication for rational prescribing | Q45126802 |
| | Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis | Q45264297 |
| | Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors | Q46447268 |
| | Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial | Q46879529 |
| | Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. | Q46957598 |
| | Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole | Q46982445 |
| | Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response? | Q53180724 |
| | One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks' treatment with esomeprazole: a randomized, placebo-controlled study. | Q53180728 |
| | Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial | Q61826600 |
| | Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland | Q72796022 |
| | Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study | Q80336249 |
| | Community-acquired pneumonia and use of gastric acid-suppressive drugs | Q81406351 |
| | A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis | Q83208440 |
| | Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams | Q83304386 |
| | A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis | Q83989365 |
| P433 | issue | 7 | |
| P921 | main subject | esomeprazole | Q553223 |
| P304 | page(s) | 627-636 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials | |
| P478 | volume | 31 | |